Amid nearly a 100% increase in invasive pneumococcal disease (IPD) between 2012 and 2024, there is an apparent need to develop pneumococcal vaccines with greater valency to protect against nonvaccine serotypes (NVTs).
Despite efficacy in the…
Amid nearly a 100% increase in invasive pneumococcal disease (IPD) between 2012 and 2024, there is an apparent need to develop pneumococcal vaccines with greater valency to protect against nonvaccine serotypes (NVTs).
Despite efficacy in the…